Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
Chaomin Wu,Xiaoyan Chen,Yanping Cai,Jia’an Xia,Xing Zhou,Sha Xu,Han-Ping Huang,Li Zhang,Xia Zhou,Chunling Du,Yuye Zhang,Juan Song,Sijiao Wang,Yencheng Chao,Zeyong Yang,Jie Xu,Xin Zhou,Dechang Chen,Weining Xiong,Lei Xu,Feng Zhou,Jinjun Jiang,Chunxue Bai,Zheng Junhua,Yuanlin Song +24 more
TLDR
Although high fever was associated with the development of ARDS, it was also associated with better outcomes among patients with ARDS and treatment with methylprednisolone may be beneficial for patients who develop ARDS.Abstract:
Importance Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. Risk factors for the clinical outcomes of COVID-19 pneumonia have not yet been well delineated. Objective To describe the clinical characteristics and outcomes in patients with COVID-19 pneumonia who developed acute respiratory distress syndrome (ARDS) or died. Design, Setting, and Participants Retrospective cohort study of 201 patients with confirmed COVID-19 pneumonia admitted to Wuhan Jinyintan Hospital in China between December 25, 2019, and January 26, 2020. The final date of follow-up was February 13, 2020. Exposures Confirmed COVID-19 pneumonia. Main Outcomes and Measures The development of ARDS and death. Epidemiological, demographic, clinical, laboratory, management, treatment, and outcome data were also collected and analyzed. Results Of 201 patients, the median age was 51 years (interquartile range, 43-60 years), and 128 (63.7%) patients were men. Eighty-four patients (41.8%) developed ARDS, and of those 84 patients, 44 (52.4%) died. In those who developed ARDS, compared with those who did not, more patients presented with dyspnea (50 of 84 [59.5%] patients and 30 of 117 [25.6%] patients, respectively [difference, 33.9%; 95% CI, 19.7%-48.1%]) and had comorbidities such as hypertension (23 of 84 [27.4%] patients and 16 of 117 [13.7%] patients, respectively [difference, 13.7%; 95% CI, 1.3%-26.1%]) and diabetes (16 of 84 [19.0%] patients and 6 of 117 [5.1%] patients, respectively [difference, 13.9%; 95% CI, 3.6%-24.2%]). In bivariate Cox regression analysis, risk factors associated with the development of ARDS and progression from ARDS to death included older age (hazard ratio [HR], 3.26; 95% CI 2.08-5.11; and HR, 6.17; 95% CI, 3.26-11.67, respectively), neutrophilia (HR, 1.14; 95% CI, 1.09-1.19; and HR, 1.08; 95% CI, 1.01-1.17, respectively), and organ and coagulation dysfunction (eg, higher lactate dehydrogenase [HR, 1.61; 95% CI, 1.44-1.79; and HR, 1.30; 95% CI, 1.11-1.52, respectively] and D-dimer [HR, 1.03; 95% CI, 1.01-1.04; and HR, 1.02; 95% CI, 1.01-1.04, respectively]). High fever (≥39 °C) was associated with higher likelihood of ARDS development (HR, 1.77; 95% CI, 1.11-2.84) and lower likelihood of death (HR, 0.41; 95% CI, 0.21-0.82). Among patients with ARDS, treatment with methylprednisolone decreased the risk of death (HR, 0.38; 95% CI, 0.20-0.72). Conclusions and Relevance Older age was associated with greater risk of development of ARDS and death likely owing to less rigorous immune response. Although high fever was associated with the development of ARDS, it was also associated with better outcomes among patients with ARDS. Moreover, treatment with methylprednisolone may be beneficial for patients who develop ARDS.read more
Citations
More filters
Journal ArticleDOI
Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.
Valentina Morena,Laura Milazzo,Letizia Oreni,Giovanna Bestetti,Tommaso Fossali,Cinzia Bassoli,Alessandro Torre,Maria Vittoria Cossu,Caterina Minari,Elisabetta Ballone,Andrea Perotti,Davide Mileto,Fosca Niero,Stefania Merli,Antonella Foschi,Stefania Vimercati,Giuliano Rizzardini,Salvatore Sollima,Lucia Bradanini,Laura Galimberti,Riccardo Colombo,Valeria Micheli,C. Negri,Anna Lisa Ridolfo,Luca Meroni,Massimo Galli,Spinello Antinori,Mario Corbellino +27 more
TL;DR: Tocilizumab exerts a rapidly beneficial effect on fever and inflammatory markers, although no significant impact on the clinical outcome can be inferred by the results.
Journal ArticleDOI
IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study
José María Galván-Román,Sebastián C Rodríguez-García,Emilia Roy-Vallejo,Ana Marcos-Jimenez,Santiago Sánchez-Alonso,C. Fernández-Díaz,Ana Alcaraz-Serna,Tamara Mateu-Albero,Pablo Rodriguez-Cortes,Ildefonso Sánchez-Cerrillo,Laura Esparcia,Pedro Martínez-Fleta,Celia López-Sanz,Ligia Gabrie,Luciana del Campo Guerola,Carmen Suárez-Fernández,Julio Ancochea,Alfonso Canabal,Patricia Albert,Diego A Rodríguez-Serrano,Juan Mariano Aguilar,Carmen Del Arco,Ignacio Santos,Lucio García-Fraile,Rafael de la Cámara,José María Serra,Esther Limón Ramírez,Tamara Alonso,Pedro Landete,Joan B. Soriano,Enrique Martin-Gayo,Arturo Fraile Torres,Nelly D. Zurita Cruz,Rosario García-Vicuña,Laura Cardeñoso,Francisco Sánchez-Madrid,Arantzazu Alfranca,Cecilia Muñoz-Calleja,Isidoro González-Álvaro +38 more
TL;DR: Baseline IL-6 levels>30 pg/ml predicts IMV requirement in patients with COVID-19 and contributes to establish an adequate indication for TCZ administration.
Journal ArticleDOI
Inflammasome activation in infected macrophages drives COVID-19 pathology
Esen Sefik,Rihao Qu,Caroline Junqueira,Eleanna T. Kaffe,Haris Mirza,Jun Zhao,J. Richard Brewer,Ailin Han,Holly R. Steach,Benjamin Israelow,Holly N. Blackburn,Sofia E. Velazquez,Y. Grace Chen,Stephanie Halene,Akiko Iwasaki,Eric Meffre,Michel C. Nussenzweig,Judy Lieberman,Craig B. Wilen,Yuval Kluger,Richard A. Flavell +20 more
TL;DR: In this paper , the authors showed that SARS-CoV-2 infection and replication in lung resident human macrophages is a critical driver of lung pathology, as inhibition of the NLRP3 inflammasome pathway reversed chronic lung pathology.
Journal ArticleDOI
Animal and translational models of SARS-CoV-2 infection and COVID-19.
Matt D. Johansen,Aaron T. Irving,X. Montagutelli,Michelle D. Tate,Michelle D. Tate,Ina Rudloff,Ina Rudloff,Marcel F. Nold,Marcel F. Nold,Nicole G. Hansbro,Nicole G. Hansbro,Richard Kim,Richard Kim,Chantal Donovan,Chantal Donovan,Gang Liu,Gang Liu,Alen Faiz,Kirsty R. Short,J. G. Lyons,Geoffrey W. McCaughan,Mark D. Gorrell,Alexander J. Cole,Courtney C. Moreno,David G. Le Couteur,Daniel Hesselson,James A. Triccas,G. Gregory Neely,Jennifer R. Gamble,Stephen J. Simpson,Bernadette M. Saunders,Brian G. Oliver,Brian G. Oliver,Warwick J. Britton,Peter A. B. Wark,Claudia A. Nold-Petry,Claudia A. Nold-Petry,Philip M. Hansbro,Philip M. Hansbro +38 more
TL;DR: The diverse animal, cell and tissue models that are being used and developed are explored and collectively recapitulate many critical aspects of disease manifestation in humans to develop and test new preventions and treatments.
Journal ArticleDOI
Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis.
Nicola Potere,Emanuele Valeriani,Matteo Candeloro,Marco Tana,Ettore Porreca,Antonio Abbate,Silvia Spoto,Anne W S Rutjes,Marcello Di Nisio +8 more
TL;DR: Mortality was very high in critically ill patients based on very low-quality evidence due to striking heterogeneity and risk of bias, although reported by only one third of the studies suggesting considerable underreporting.
References
More filters
Journal ArticleDOI
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
Journal ArticleDOI
A Novel Coronavirus from Patients with Pneumonia in China, 2019.
Na Zhu,Dingyu Zhang,Wenling Wang,Xingwang Li,Bo Yang,Jingdong Song,Xiang Zhao,Baoying Huang,Weifeng Shi,Roujian Lu,Peihua Niu,Faxian Zhan,Xuejun Ma,Dayan Wang,Wenbo Xu,Wenbo Xu,Guizhen Wu,George F. Gao,Wenjie Tan +18 more
TL;DR: Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily, which is the seventh member of the family of coronaviruses that infect humans.
Journal ArticleDOI
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou,Xing-Lou Yang,Xian Guang Wang,Ben Hu,Lei Zhang,Wei Zhang,Hao Rui Si,Yan Zhu,Bei Li,Chao Lin Huang,Hui-Dong Chen,Jing Chen,Yun Luo,Hua Guo,Ren Di Jiang,Meiqin Liu,Ying Chen,Xu Rui Shen,Xi Wang,Xiao Shuang Zheng,Kai Zhao,Quanjiao Chen,Fei Deng,Lin Lin Liu,Bing Yan,Fa Xian Zhan,Yan-Yi Wang,Gengfu Xiao,Zhengli Shi +28 more
TL;DR: Identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China, and it is shown that this virus belongs to the species of SARSr-CoV, indicates that the virus is related to a bat coronav virus.
Journal ArticleDOI
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
Dawei Wang,Bo Hu,Chang Hu,Fangfang Zhu,Xing Liu,Jing Zhang,Binbin Wang,Hui Xiang,Zhenshun Cheng,Yong Xiong,Yan Zhao,Yirong Li,Xinghuan Wang,Zhiyong Peng +13 more
TL;DR: The epidemiological and clinical characteristics of novel coronavirus (2019-nCoV)-infected pneumonia in Wuhan, China, and hospital-associated transmission as the presumed mechanism of infection for affected health professionals and hospitalized patients are described.
Journal ArticleDOI
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Nanshan Chen,Min Zhou,Xuan Dong,Jie-Ming Qu,Fengyun Gong,Yang Han,Yang Qiu,Jingli Wang,Ying Liu,Yuan Wei,Jia'an Xia,Ting Yu,Xinxin Zhang,Li Zhang +13 more
TL;DR: Characteristics of patients who died were in line with the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia, and further investigation is needed to explore the applicability of the Mu LBSTA scores in predicting the risk of mortality in 2019-nCoV infection.
Related Papers (5)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more